| abstract |
A 3,6-diazabicyclo[3.1.1]heptane derivative as a RET kinase inhibitor. Disclosed are a heterocyclic derivative represented by the following chemical formula, or a pharmaceutically acceptable salt, a stereoisomer, a deuterated compound, a pharmaceutical composition, and use thereof in the preparation of a medicament for treating diseases related to RET kinase and/or mutant RET kinase. The compound exhibits excellent activity at both kinase level and cell level, and has good efficacy; meanwhile, the compound has excellent pharmacokinetic properties, selectivity, and fewer toxic side effects. (I) |